Ocular Therapeutix Inc.’s filing revealed that its 10% Owner SUMMER ROAD LLC acquired Company’s shares for reported $47986.0 on Feb 23. In the deal valued at $4.80 per share,10,000 shares were bought. As a result of this transaction, SUMMER ROAD LLC now holds 5,944,761 shares worth roughly $ 21.64 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, SUMMER ROAD LLC bought 40,000 shares, generating $199,940 in total proceeds. Upon buying the shares at $5.00, the 10% Owner now owns 5,934,761 shares.
Before that, SUMMER ROAD LLC bought 4,023 shares. Ocular Therapeutix Inc. shares valued at $20,920 were divested by the 10% Owner at a price of $5.20 per share. As a result of the transaction, SUMMER ROAD LLC now holds 5,894,761 shares, worth roughly $21.46 million.
Meanwhile, H.C. Wainwright upgraded its Ocular Therapeutix Inc. [OCUL] rating to a Buy from a a Neutral in a research note published on Tuesday. PT values the company’s stock at a premium of 78.59 to its Tuesday closing price. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in late December from “a Buy” to “a Neutral”. Berenberg began covering OCUL with a “Buy” recommendation on December 17, 2020. Raymond James maintained its rating on November 13, 2020. It rated OCUL as “a Strong buy”.
Price Performance Review of OCUL
On Tuesday, Ocular Therapeutix Inc. [NASDAQ:OCUL] saw its stock fall -2.67% to $3.64. On the same session, the stock had its day’s lowest price of $3.59, but rose to a high of $3.91. Over the last five days, the stock has gained 1.96%. Ocular Therapeutix Inc. shares have fallen nearly -47.78% since the year began. Nevertheless, the stocks have fallen -73.87% over the past one year. While a 52-week high of $14.77 was reached on 01/03/22, a 52-week low of $2.91 was recorded on 05/27/22. SMA at 50 days reached $3.62, while 200 days put it at $6.24. A total of 0.63 million shares were traded, compared to the trading of 0.49 million shares in the previous session.
Levels Of Support And Resistance For OCUL Stock
The 24-hour chart illustrates a support level at 3.52, which if violated will result in even more drops to 3.39. On the upside, there is a resistance level at 3.84. A further resistance level may holdings at 4.03. The Relative Strength Index (RSI) on the 14-day chart is 52.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.16%. Stochastics %K at 60.22% indicates the stock is a holding.
How much short interest is there in Ocular Therapeutix Inc.?
A steep rise in short interest was recorded in Ocular Therapeutix Inc. stocks on Apr 28, 2022, dropping by -0.18 million shares to a total of 4.01 million shares. Yahoo Finance data shows the prior-month short interest on Mar 30, 2022 was 4.19 million shares. There was a decline of -4.49%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.69% of the overall stock float, the days-to-cover ratio (short ratio) fell to 6.06.
Ocular Therapeutix Inc. [OCUL] – Who Are The Largest Shareholders?
In filings from Opaleye Management, Inc., it is revealed that the company now owns 5,974,800 shares, or roughly 7.78% of the outstanding OCUL shares. In other words, the investor’s shares have fallen by 0 from its previous 13-F filing of 5974800.0. Additionally, Summer Road LLC increased 3.12% of its stake after which the total value it holdings stand at $18,607,102, while BlackRock Fund Advisors reduced -0.36% of its stake to hold $14.23 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 113,455 shares of Ocular Therapeutix Inc., while Deltec Asset Management LLC bought -19,000 shares. At present, SSgA Funds Management, Inc. is holding 1,704,934 shares valued at $5.34 million. Citadel Advisors LLC owned 1,692,336 shares of the company at the time of its most recent 13F filing, worth $5.3 million.
According to FactSet, Ocular Therapeutix Inc.’s share price will average $15.83 in the next year, based on opinions of analysts polled by the firm. This is up nearly 301.07 percent from its previous closing price of $3.74. Analysts expect Ocular Therapeutix Inc. stock to reach the higher price of $29.00, while the lowest price estimate is $5.00. However, 6 analysts have rated OCUL stock as a Buy in their predictions for 2022. The most recent change occurred on August 10, 2020 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $13.